Gonadotropin-releasing hormone agonist is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include RenJi Hospital (1) and Shengjing Hospital (1). Registered phases: Phase 2/3 and Phase 2. Conditions studied include Tubular Breast Cancer; Mucinous Breast Cancer; Invasive Ductal Breast Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05638594 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer |
Phase 2 | Recruiting |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (ClinicalTrials.gov ↗) Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer |
Phase 2/3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Tubular Breast Cancer | 1 |
| Mucinous Breast Cancer | 1 |
| Invasive Ductal Breast Cancer | 1 |
| Inflammatory Breast Cancer | 1 |
| Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| RenJi Hospital | 1 |
| Shengjing Hospital | 1 |
| Register | Gonadotropin-releasing hormone agonist trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gonadotropin-releasing hormone agonist works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gonadotropin-releasing hormone agonist (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.